Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2022 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to check if management speaks about counterparties' business as part of its own, with the company already inside that growth, and the counterparties' trajectory early and large relative to the company. In the transcript, the company is Cue Biopharma, a biotech developing immunotherapies. They talk about their own clinical trials, their own pipeline, their own development. They mention partnerships? They mention "corporate partnering" as a strategic position, but not specific counterparties. They talk about their own trials, their own patients, their own data. They mention "principal investigators" but that's not a counterparty scaling. They mention "Fast Track designation" from FDA, but that's regulatory. They mention "we have treated our first patient with CUE-102" etc. They talk about their own plans for registrational trials. They don't describe any specific customer, partner, licensee, distributor, etc., that is scaling up and driving their business. They mention "we believe the data supports the premise... placing us in a strategic position for corporate partnering" but that's about potential future partnerships, not existing ones. They don't narrate any counterparty's own ramp. So the answer is NO. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.